225 related articles for article (PubMed ID: 35471602)
1. Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials.
Fujiwara Y; Horita N; Harrington M; Namkoong H; Miyashita H; Galsky MD
Cancer Immunol Immunother; 2022 Dec; 71(12):2837-2848. PubMed ID: 35471602
[TBL] [Abstract][Full Text] [Related]
2. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
Fujiwara Y; Horita N; Namkoong H; Galsky MD
Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
Guo X; Li W; Hu J; Zhu EC; Su Q
Eur J Clin Pharmacol; 2020 Oct; 76(10):1345-1354. PubMed ID: 32507925
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known.
Zheng C; Huang S; Lin M; Hong B; Ni R; Dai H; Lin X; Yang J
Hepatol Commun; 2023 Mar; 7(3):e0063. PubMed ID: 36802366
[TBL] [Abstract][Full Text] [Related]
5. Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials.
Fujiwara Y; Horita N; Adib E; Zhou S; Nassar AH; Asad ZUA; Cortellini A; Naqash AR
Lancet Oncol; 2024 Jan; 25(1):62-75. PubMed ID: 38012893
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Pan J; Liu Y; Guo X; Bai Z; Levi Sandri GB; Méndez-Sánchez N; Qi X
Expert Opin Drug Saf; 2022 Oct; 21(10):1275-1287. PubMed ID: 36214583
[TBL] [Abstract][Full Text] [Related]
7. Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials.
Zhou S; Horita N; Shao T; Harrington M; Fujiwara Y
Ther Adv Med Oncol; 2024; 16():17588359241257874. PubMed ID: 38845790
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
Ngongondo M; Miyahara S; Hughes MD; Sun X; Bisson GP; Gupta A; Kumwenda J; Lavenberg JA; Torres TS; Nyirenda M; Kidonge KK; Hosseinipour MC;
J Acquir Immune Defic Syndr; 2018 May; 78(1):54-61. PubMed ID: 29406428
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis.
Fu J; Li WZ; McGrath NA; Lai CW; Brar G; Xiang YQ; Xie C
Front Oncol; 2021; 11():650292. PubMed ID: 33968750
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients: A network meta-analysis.
Wu Z; Chen S; Du X; Wu Y; Xie X
J Clin Pharm Ther; 2021 Apr; 46(2):310-318. PubMed ID: 33031574
[TBL] [Abstract][Full Text] [Related]
12. Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients.
Zarrabi K; Wu S
Oncology; 2018; 94(5):259-273. PubMed ID: 29539626
[TBL] [Abstract][Full Text] [Related]
13. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Abdel-Rahman O; ElHalawani H; Fouad M
Expert Opin Drug Saf; 2015 Oct; 14(10):1507-18. PubMed ID: 26394770
[TBL] [Abstract][Full Text] [Related]
14. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Deng S; Yang Q; Shu X; Lang J; Lu S
Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
[No Abstract] [Full Text] [Related]
15. Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus.
Lin Z; Zhang X; Zhou Y; Chen C; He LN; Li H; Wang Y; Chen T; Hong S; Zhang L
Cancer Immunol Immunother; 2022 May; 71(5):1247-1255. PubMed ID: 34647153
[TBL] [Abstract][Full Text] [Related]
16. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
Chan SL; Yip TC; Wong VW; Tse YK; Yuen BW; Luk HW; Lui RN; Chan HL; Mok TS; Wong GL
Cancer Med; 2020 Oct; 9(19):7052-7061. PubMed ID: 32780516
[TBL] [Abstract][Full Text] [Related]
17. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.
Wang W; Lie P; Guo M; He J
Int J Cancer; 2017 Sep; 141(5):1018-1028. PubMed ID: 28263392
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors.
Miller ED; Abu-Sbeih H; Styskel B; Nogueras Gonzalez GM; Blechacz B; Naing A; Chalasani N
Am J Gastroenterol; 2020 Feb; 115(2):251-261. PubMed ID: 31789632
[TBL] [Abstract][Full Text] [Related]
19. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Opin Drug Saf; 2014 Aug; 13(8):999-1008. PubMed ID: 24930544
[TBL] [Abstract][Full Text] [Related]
20. Nitazoxanide for chronic hepatitis C.
Nikolova K; Gluud C; Grevstad B; Jakobsen JC
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD009182. PubMed ID: 24706397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]